Jul 29, 2019 / 12:00PM GMT
Operator
Good day, ladies and gentlemen, and welcome to the Cidara Therapeutic's Phase II STRIVE B Clinical Trial Results Conference Call. (Operator Instructions) As a reminder, this conference may be recorded.
I would now like to turn the conference over to Westwicke Partners, Robert Uhl. You may begin.
Robert H. Uhl - Westwicke Partners, LLC - MD
Thank you, operator. Good morning, everyone, and welcome to Cidara's conference call to provide top line results from the STRIVE B Phase II clinical trial of rezafungin for the treatment of candidemia and invasive candidiasis. Before we begin, I'd like to let you know that on this call, the Cidara team will reference data that are presented on a set of slides that you can access from the homepage of Cidara's website. The complete set of top line data from the STRIVE B trial is contained in this morning's press release. Joining me on the call from Cidara are Jeff Stein, President and Chief Executive Officer; Taylor Sandison, Chief Medical Officer; Jamie Levine, Chief Financial Officer; Paul Daruwala, Chief Operating
Cidara Therapeutics Inc to Discuss the Phase 2 STRIVE B Results Call Transcript
Jul 29, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers